On March 17, 2015, Actavis (NYSE:ACT) completed the acquisition of Allergan, creating a $23 billion diversified global pharmaceutical company and a leader in a new industry model - Growth Pharma. The combined company has broad commercial reach extending across approximately 100 countries and is anchored by strong and sustainable brand franchises, a leading global generics business, a premier pipeline, highly efficient operations and an experienced management team. Learn more about this exciting combination at www.Actavis.com.
Allergan's products are uniformly grounded in the deepest regard for the life that each patient leads.
Our products make a difference in the way people feel and function every day. We continually conduct research to develop products that enable medical specialists to help people preserve and protect their vision, move freely, best express their inner beauty and lead healthy and active lives. Our dedication to this goal is marked by a tireless resolve to understand and address the unmet needs and wants of patients. With a heritage of more than 60 years of discovery and research, our products have made a meaningful difference in how medical conditions are treated and in the quality of patients' lives worldwide.